LOKELMA 5 GM Powder for Oral Suspension + Placebos
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus With Kidney Complications
Conditions
Type 2 Diabetes Mellitus With Kidney Complications
Trial Timeline
Oct 1, 2019 → Dec 1, 2021
NCT ID
NCT04063930About LOKELMA 5 GM Powder for Oral Suspension + Placebos
LOKELMA 5 GM Powder for Oral Suspension + Placebos is a approved stage product being developed by AstraZeneca for Type 2 Diabetes Mellitus With Kidney Complications. The current trial status is unknown. This product is registered under clinical trial identifier NCT04063930. Target conditions include Type 2 Diabetes Mellitus With Kidney Complications.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04063930 | Approved | UNKNOWN |
Competing Products
20 competing products in Type 2 Diabetes Mellitus With Kidney Complications